Tag: Zydus Lifesciences
Zydus Lifesciences records revenue growth of Rs 195,474 million in FY24
Zydus Lifesciences reports stellar financial performance for Q4 & FY24 with significant increases in revenue, EBITDA, and net profit; the board recommends a 300% dividend
Zydus completes EPICS-IIITM trial enrollment for Saroglitazar Mg in PBC treatment
Zydus Lifesciences achieves a milestone in its research by successfully enrolling participants for the EPICS-IIITM Phase 2b/3 trial, evaluating Saroglitazar Mg's efficacy in treating Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease
Zydus Lifesciences acquires 6.5% stake in Mylab via its subsidiary ZAHIL
The acquisition represents collective vision to transform healthcare by combining therapeutic expertise in human formulations and diagnostic capabilities of the two companies
Zydus’s two-dose Covid-19 vaccine, ZyCoV-D receives EUA from DCGI
The two-dose regimen has been approved in the age group of 12 years and above
Zydus subsidiary supported drug data for Menkes disease set to be...
Fortress Biotech and Cyprium Therapeutics alongwith Zydus Lifesciences’ Sentynl Therapeutics announce CUTX-101, copper histidinate data to be presented at 2022 American College of Medical Genetics Annual Clinical Genetics Meeting
Digitalization in pharma operations inevitable but challenges remain: Top CEOs
Industry captains and regulators in the ecosystem deliberate on achieving excellence and quality in operations, vaccine development and sustainability